Workup for AKI on CKD
For a patient admitted with acute kidney injury superimposed on chronic kidney disease, immediately obtain: serum creatinine, BUN, complete blood count, comprehensive metabolic panel, urinalysis with microscopy, urine protein-to-creatinine ratio, and renal ultrasound to exclude obstruction—while simultaneously conducting a focused assessment for nephrotoxin exposure, volume status, and precipitating causes. 1
Initial Laboratory Evaluation
Blood work:
- Serum creatinine and BUN (compare to baseline if available)
- Complete blood count with differential
- Comprehensive metabolic panel (electrolytes, calcium, phosphate, bicarbonate)
- Serum potassium (critical in patients on ACE inhibitors, ARBs, or MRAs) 2
Urine studies:
- Urinalysis with microscopy looking specifically for:
- Red blood cell casts and dysmorphic RBCs (suggests glomerular disease)
- White blood cells and organisms (infection)
- Epithelial cells and granular casts (acute tubular necrosis)
- Urine chemistry including fractional excretion of sodium 3
- Urine protein-to-creatinine or albumin-to-creatinine ratio 2, 1
The urine microscopy is particularly critical—tea-colored urine with proteinuria >2+, red blood cell casts, and deformed red blood cells indicate glomerular pathology requiring different management than prerenal or obstructive causes 1.
Imaging
Renal ultrasound is mandatory to:
- Exclude urinary tract obstruction (postrenal cause)
- Assess kidney size (small echogenic kidneys suggest chronicity and pre-existing CKD)
- Identify structural abnormalities (hydronephrosis, scarring, masses)
- Evaluate before potential kidney biopsy 1
Ultrasound should ideally be performed after correcting hypovolemia if present 4. Note that obstruction accounts for <3% of AKI cases, but missing it has significant therapeutic implications 1.
Critical History Elements
Nephrotoxin exposure assessment:
- NSAIDs (most common culprit)
- Aminoglycosides, vancomycin
- ACE inhibitors/ARBs (note: up to 30% creatinine rise is acceptable, not true AKI) 2
- Contrast media exposure
- Herbal medications and over-the-counter drugs 5, 4
Volume status indicators:
- Recent vomiting, diarrhea, bleeding
- Diuretic use
- Hypotension or shock
- Heart failure exacerbation 1
Infection/sepsis screening:
- Fever, source of infection
- Sepsis is a leading cause of AKI in hospitalized patients 1
Physical Examination Priorities
- Volume status: Orthostatic vital signs, jugular venous pressure, peripheral edema, mucous membranes
- Blood pressure: Hypertension suggests volume overload or underlying CKD complications 2
- Cardiovascular: Signs of heart failure
- Skin: Rashes suggesting systemic vasculitis or atheroembolic disease 3
Additional Considerations Based on CKD Stage
If eGFR <60 mL/min/1.73 m² (Stage 3 or higher):
- Hemoglobin (assess for anemia of CKD)
- Parathyroid hormone, vitamin D, calcium, phosphate (metabolic bone disease screening)
- These complications become more prevalent and severe as CKD progresses 2
The frequency of monitoring should increase with CKD severity: every 6-12 months for Stage 3, every 3-5 months for Stage 4, and every 1-3 months for Stage 5 2.
When to Consider Kidney Biopsy
Biopsy may be indicated when:
- Glomerulonephritis or vasculitis is suspected (nephritic/nephrotic syndrome)
- Cause remains unclear after initial workup
- Rapidly progressive kidney function decline 1
However, biopsy has shown limited therapeutic impact in most AKD cases without clear AKI, so risks must be carefully weighed 4.
Immediate Management Priorities During Workup
Nephrotoxin management:
- Discontinue NSAIDs immediately
- Hold ACE inhibitors/ARBs if volume depleted or creatinine rises >30% 2
- Review and adjust all renally-eliminated medications 5
- Avoid iodinated contrast unless absolutely necessary 1
Volume optimization:
- Use isotonic crystalloids (not colloids or starches) for volume expansion 6
- Document fluid balance 7
- Treat hypotension if present (50.7% of AKI-on-CKD cases have systemic hypotension as contributing factor) 7
Common Pitfalls to Avoid
Do not confuse expected creatinine rise with ACE inhibitors/ARBs (<30%) with true AKI—these medications should not be stopped for modest increases in stable patients 2
Do not assume obstruction is unlikely—always get ultrasound, especially in older men 3
Do not extrapolate CKD drug dosing to AKI—the time course and metabolic effects differ significantly 5
Do not delay nephrology consultation—median time to referral is 24 hours but earlier consultation improves outcomes, particularly for Stage 2-3 AKI 7
The variables related to the acute injury (AKI severity, precipitating cause, ATN-ISS score) are more predictive of outcomes than the underlying CKD stage itself 8. This underscores the importance of aggressively identifying and treating the acute insult.